Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 4NETWORK 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced BRAF-mutant Cancers 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2330Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × PX-866 × Clear all
NCT01259869 2023-08-22

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Canadian Cancer Trials Group

Phase 2 Completed
34 enrolled 7 charts
CNS

Glioblastoma

NCT01331083 2023-08-22

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Completed
68 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00726583 2018-05-17

Phase I Trial of Oral PX-866

Seagen Inc.

Phase 1 Completed
90 enrolled

Carcinoma, Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01204099 2018-05-16

Study of PX-866 and Docetaxel in Solid Tumors

Seagen Inc.

Phase 1/2 Completed
223 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

NCT01616199 2018-05-16

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Seagen Inc.

Phase 1/2 Terminated
24 enrolled

Advanced BRAF-mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡